Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
DWI-Leibniz-Institute für Interaktive Materialien e.V. | Aachen, Nordrhein Westfalen | Germany | about 2 months ago
to develop further both professionally and personally in an interdisciplinary setting. Position The DWI is looking for a Postdoctoral researcher to develop new granular biomaterials for tissue engineering
-
15 Jan 2026 Job Information Organisation/Company Ghent University Research Field Biological sciences » Other Chemistry » Biochemistry Medical sciences » Other Technology » Biotechnology Researcher
-
investigators, graduate students, and staff regarding health concerns, and / or husbandry issues; provides technical services for investigators including blood and tissue collection and anesthetic induction
-
28 Nov 2025 Job Information Organisation/Company University of Aveiro Department CICECO - Aveiro Institute of Materials Research Field Chemistry Chemistry » Biochemistry Engineering » Materials
-
Knowledge and skills in formulation and characterization of polymeric materials and composites Skills in additive manufacturing Desired requirements Knowledge and experience in tissue engineering Skills in in
-
every level of biological organization: genes, metabolism, cells, blood, tissues, organs, etc. It is implicated in 80+ autoimmune diseases, 400+ primary immune disorders, thousands of immune-inducing
-
, organisation, engineering Additional Information Website for additional job details https://www.ucd.ie/ Work Location(s) Number of offers available1Company/InstituteUniversity College
-
About the Lab: We are seeking a Postdoctoral Scientist to join the Henry Lab at the Massachusetts Institute of Technology (MIT), led by Dr. Whitney Henry, an HHMI Freeman Hrabowski Scholar
-
Tissue Engineering, College of Biomedical Engineering) and the Psychiatric Neuroscience Lab, led by Dr. Matteo Martino (Graduate Institute of Mind, Brain, and Consciousness) and Dr. Paola Magioncalda
-
engineer (IR) for a 12-month period, aims to develop a new generation of anticancer drugs called degraders (PROteolysis TArgeting Chimeras, PROTACs). These innovative molecules do not simply block a target